日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2)

雷莫芦单抗治疗中晚期肝细胞癌伴甲胎蛋白升高患者：两项 3 期研究（REACH 和 REACH-2）的汇总结果

期刊:Liver Cancer
影响因子:9.1
doi:10.1159/000516605
Kudo, Masatoshi; Finn, Richard S; Morimoto, Manabu; Rau, Kun-Ming; Ikeda, Masafumi; Yen, Chia-Jui; Galle, Peter R; Llovet, Josep M; Daniele, Bruno; Lim, Ho Yeong; McIlwain, David W; Yoshikawa, Reigetsu; Nakamura, Kenichi; Liang, Kun; Wang, Chunxiao; Abada, Paolo; Widau, Ryan C; Zhu, Andrew X
细胞生物学
肿瘤
肿瘤免疫
发表日期：2021
文献求助 收藏

Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2

雷莫芦单抗对晚期肝细胞癌患者ALBI分级的影响：REACH和REACH-2研究结果

期刊:Jhep Reports
影响因子:7.5
doi:10.1016/j.jhepr.2020.100215
Kudo, Masatoshi; Galle, Peter R; Brandi, Giovanni; Kang, Yoon-Koo; Yen, Chia-Jui; Finn, Richard S; Llovet, Josep M; Assenat, Eric; Merle, Philippe; Chan, Stephen L; Palmer, Daniel H; Ikeda, Masafumi; Yamashita, Tatsuya; Vogel, Arndt; Huang, Yi-Hsiang; Abada, Paolo B; Yoshikawa, Reigetsu; Shinozaki, Kenta; Wang, Chunxiao; Widau, Ryan C; Zhu, Andrew X
细胞生物学
肿瘤
肿瘤免疫
发表日期：2021
文献求助 收藏

Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial

在既往接受索拉非尼治疗的晚期肝细胞癌合并甲胎蛋白升高患者中，使用雷莫芦单抗治疗：REACH-2试验的日本亚组分析

期刊:Journal of Gastroenterology
影响因子:5.5
doi:10.1007/s00535-020-01668-w
Kudo, Masatoshi; Okusaka, Takuji; Motomura, Kenta; Ohno, Izumi; Morimoto, Manabu; Seo, Satoru; Wada, Yoshiyuki; Sato, Shinpei; Yamashita, Tatsuya; Furukawa, Masayuki; Aramaki, Takeshi; Nadano, Seijin; Ohkawa, Kazuyoshi; Fujii, Hirofumi; Kudo, Toshihiro; Furuse, Junji; Takai, Hiroki; Homma, Gosuke; Yoshikawa, Reigetsu; Zhu, Andrew X
细胞生物学
肿瘤
肿瘤免疫
发表日期：2020
文献求助 收藏

Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial

一线S-1联合奥沙利铂（含或不含雷莫芦单抗）序贯紫杉醇联合雷莫芦单抗治疗东亚晚期胃癌的疗效：RAINSTORM II期随机临床试验

期刊:Jama Network Open
影响因子:9.7
doi:10.1001/jamanetworkopen.2019.8243
Yoshikawa, Takaki; Muro, Kei; Shitara, Kohei; Oh, Do-Youn; Kang, Yoon-Koo; Chung, Hyun Cheol; Kudo, Toshihiro; Chin, Keisho; Kadowaki, Shigenori; Hamamoto, Yasuo; Hironaka, Shuichi; Yoshida, Kazuhiro; Yen, Chia-Jui; Omuro, Yasushi; Bai, Li-Yuan; Maeda, Kaijiro; Ozeki, Akichika; Yoshikawa, Reigetsu; Kitagawa, Yuko
胃癌
肿瘤
肿瘤免疫
发表日期：2019
文献求助 收藏

Trimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stage II/III esophageal squamous cell carcinoma patients

食管切除术联合新辅助放化疗的三联疗法可提高临床II/III期食管鳞状细胞癌患者的生存率。

期刊:Oncology Reports
影响因子:3.9
doi:10.3892/or.2012.1847
Fujiwara, Yoshinori; Yoshikawa, Reigetsu; Kamikonya, Norihiko; Nakayama, Tsuyoshi; Kitani, Kotaro; Tsujie, Masanori; Yukawa, Masao; Inoue, Masatoshi; Yamamura, Takehira
细胞生物学
肿瘤
肿瘤免疫
发表日期：2012
文献求助 收藏